Parmax Pharma Limited reported audited standalone earnings results for the fourth quarter and full year ended March 31, 2021. For the quarter, the company reported revenue from operations of INR 73,913,010. Total income was INR 74,147,050. Loss for the period was INR 3,031,976. Basic loss per share was INR 0.81. For the year, the company reported revenue from operations of INR 262,045,442. Total income was INR 262,934,050. Profit for the period was INR 7,544,218. Basic earnings per share was INR 2.02.